Filing Flows

Filing Flows › Rigel Pharmaceuticals (RIGL) › Next earnings date

Rigel Pharmaceuticals (RIGL) earnings: missed the estimate

Rigel Pharmaceuticals (RIGL) reported on Nov 5, 2026 and missed the EPS estimate: $0.65 against $0.96 (-32.5%). Revenue was $80.9M for Q3 2026, +16% year over year. It beat the EPS estimate in 40% of the quarters on record.

Last result−32.5% vs estimate
Beat rate40%

The last report

Rigel Pharmaceuticals reported revenue of $80.9M for the third quarter 2026 (+16% Y/Y), net earnings $13.2M: Product sales, net $72.3M, Contract revenues from collaborations and other $8.6M. How it makes money → · Every quarter →

Rigel Pharmaceuticals: EPS against the estimate, last 5 reportsRigel Pharmaceuticals: EPS against the estimate, last 5 reportsEstimateReported$0.94$1.46Nov 25$1.20$1.12Mar 26$0.87$0.44May 26−$0.08$0.88Aug 26$0.96$0.65Nov 26
Latest (Nov 26): Estimate $0.96, Reported $0.65.

Rigel Pharmaceuticals' latest quarter

Rigel Pharmaceuticals, Q3 2026: revenue $80.9M (+16% year over year), operating margin 21.1%, net earnings $13.2M, operating cash flow $34.6M. The chart follows the revenue to costs, profit and cash.

Questions

Did Rigel Pharmaceuticals beat earnings?

Rigel Pharmaceuticals (RIGL) reported on Nov 5, 2026 and missed the EPS estimate: $0.65 against $0.96 (-32.5%).

When does RIGL report earnings?

The next date is not set yet.

Does Rigel Pharmaceuticals usually beat earnings?

It beat the consensus EPS estimate in 40% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.